In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elite Pharmaceuticals, Inc.

https://www.elitepharma.com/

Latest From Elite Pharmaceuticals, Inc.

China Lays Out Requirements For Biosimilar Extrapolation

In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.

China Coronavirus COVID-19

Two New Vaccines Join COVID Fight As China Ships Millions Overseas

CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as  Beijing shipping millions of doses around the world.

China Coronavirus COVID-19

One Year On: WHO Concludes Wuhan Probe; CanSino Vaccine 66% Effective

A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.

China Vaccines

China Approves SinoVac's CoronaVac, As 50.6% Efficacy Reported

SinoVac has obtained conditional approval in China for its COVID-19 vaccine CoronaVac, while new clinical data released by the company show a large difference in protection rates in two separate trials, in one case barely above the WHO threshold.

China Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Elite Laboratories, Inc.
UsernamePublicRestriction

Register